share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bozic Carmen

SEC announcement ·  Feb 28 05:58
Summary by Futu AI
Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,309 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of approximately $1.43 million. Following the sale, Bozic's direct holdings in the company amount to 36,939 shares. The sale was executed to cover the payment of exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.
Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,309 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of approximately $1.43 million. Following the sale, Bozic's direct holdings in the company amount to 36,939 shares. The sale was executed to cover the payment of exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.